

# Philippines

The fast-growing population and the progressive government investment in healthcare are boosting the pharmaceutical industry in the country

## Risk and reward index

**48.6**  
Industry Rewards

**42.7**  
Industry Risk

**14**  
Regional Rank

**69**  
Global Rank

Note: Scores out of 100; higher score = lower risk. Source: Fitch Solutions' Innovative Pharmaceuticals Risk/Reward Index


## Key foreign players

- 1 AstraZeneca
- 2 GlaxoSmithKline
- 3 Novartis
- 4 Merck & Co
- 5 Pfizer
- 6 Sanofi
- 7 Takeda
- 8 Johnson & Johnson


## Strengths



Government committed to **expand universal healthcare coverage**



Significant **pharmaceutical market growth**



**Strong local manufacturing sector**



Great efforts to **suppress counterfeit drugs**

## Challenges



Financial sustainability of the **healthcare system**



Vast **regional disparities** in **healthcare coverage and access**




Uncertain **pricing regulation**



Low levels of **intellectual property protection**

## Forecast

■ Pharmaceutical sales, USDbn ■ Pharmaceutical sales, % of GDP



Source: Philippines, Pharmaceuticals & Healthcare Report Q2 2020, Fitch Solutions

## Regulations

Pharmaceutical registration and regulations are overseen by the Philippines **Food and Drug Administration (FDA)**, under the **Department of Health**.

Every **imported pharmaceutical** must be registered with the Philippines **FDA** prior to market entry.

**Foreign drug companies** account for a **substantial percentage** of the Filipino **pharmaceutical market**. Furthermore, with the **implementation of universal healthcare**, sales growth **opportunities** for **foreign drug companies** should **increase** considerably.